Xylem’s New Smart Wastewater Treatment Solution Cuts Operating Costs and Reduces Energy Use by 25%
7.4.2022 15:00:00 EEST | Business Wire | Press release
Wastewater utilities can now achieve compliance targets while cutting energy consumption from aeration by up to 25% with Xylem Edge Control. This off-the-shelf suite of digital solutions for conventional activated sludge (CAS) plants marks the latest breakthrough in the digitization of water utilities. With Xylem Edge Control, wastewater operators can now control and monitor their assets, improve nutrient removal, save energy and reduce costs.
“Wastewater utilities are constantly balancing the need to ensure service reliability and compliance alongside the need to manage costs,” said Chris Taylor, Global Product Manager at Xylem. “Xylem Edge Control helps wastewater utilities confidently walk that line, bringing together our digital innovation expertise and insights from our deep bioprocessing experience, in a suite of solutions that maximizes process control while dramatically cutting energy consumption and supporting sustainability goals.”
“Utilities around the world are well on the way to digitizing their networks and reaping major water, energy and cost efficiencies. Xylem Edge Control is a versatile, multi-functional solution that meets wastewater utilities where they are on that journey – and sets them up to unlock more of the benefits of digital transformation.”
The Edge Control solutions apply analytics to real-time data to provide rapid process recommendations to optimize chemical usage and aeration. As utilities target emissions reductions, Edge Control is the latest high-efficiency technology that can help utilities cut energy-related greenhouse gas (GHG) emissions and make fast progress towards achieving net-zero targets. The platform can operate with any Programmable Logic Controller under various communications protocols and connect to existing hardware, including sensors and probes.
Xylem Edge Control combines four solutions:
- Xylem Edge Control Pulsed Aeration: A digital, energy saving solution that can prevent over-aeration of underloaded treatment plants. Pulsed Aeration improves the overall biological process of CAS plants, to provide adequate mixing and ultimately achieving energy savings. Research and implementation of Pulsed Aeration has shown energy savings of approximately 25% can be achieved.
- Xylem Edge Control Ammonia Removal: Xylem Edge Control Ammonia Removal determines a CAS facility's ammonia target and helps meet its nutrient discharge limits while working to maximize energy savings. It uses an advanced algorithm to match various load conditions, that can provide consistent ammonia removal and further stabilize the biological process.
- Xylem Edge Control Ammonia + Nitrogen Removal: The solution offers wastewater utilities the potential to save energy while reducing nitrate and ammonia concentrations. It uses an advanced algorithm which communicates with CAS facilities’ existing assets to optimize the achievement of nutrient compliance targets. Its patented, one-of-a-kind, AvN® wastewater treatment process1 has the ability to create a biological environment unlike anything the wastewater treatment industry has seen with its capacity to create a Nitrite shunt. This can allow for an expedited denitrification process and ultimately, increased energy savings. Research and implementation of Ammonia + Nitrogen Removal has shown energy savings of approximately 25% in addition to a reduction in Total Inorganic Nitrogen (TIN) concentration of approximately 30%.
- Xylem Edge Control P - Removal: This solution controls chemical feed pumps based on real-time phosphorus concentrations to reduce chemical usage while meeting today’s stricter phosphorus limits.
The launch of Xylem Edge Control follows rigorous field testing across North America, including Washington and Indiana, including the wastewater treatment operations serving the city of Muncie, Indiana.
“With Muncie being the home to Ball State University, the city undergoes a major swing in population from around 70,000 people while school is in session to approximately 48,000 when school is out of session,” said Jason Ingram, Plant Superintendent at Muncie Wastewater Treatment Plant in Muncie, IN, where Xylem Edge Control Pulsed Aeration has been installed. “That’s a decrease in population of over 30%. It is during these months of decreased load where we benefit from Pulsed Aeration most. With our upgrades from Xylem’s Pulsed Aeration we are able to save $5,000 a month on energy costs.”
Global water utilities account for approximately 2% of global GHG emissions – the equivalent of the world’s shipping industry. However, innovative solutions like Edge Control can help mitigate a substantial portion of the emissions generated by inefficient wastewater operations, quickly and affordably. Furthermore, by deploying readily available advanced solutions, utilities could cut the water industry’s GHG emissions by 50% across both clean water and wastewater activities.
Xylem Edge Control can be used as a stand-alone process or as a connected, subscription-based enterprise with fees based on efficiency and savings. When connected via the Cloud, Xylem Edge Control provides data visualization, allowing the customer to see the energy savings on a monthly basis; real-time data trending reports, showing details such as ammonia and TIN concentrations and alert and alarm texts/email notifications, displaying instrumentation and software status.
Xylem Edge Control Pulsed Aeration, Xylem Edge Control Ammonia Removal and Xylem Edge Control Ammonia + Nitrogen Removal are now available for purchase globally. Xylem Edge Control P – Removal will be available to customers globally later this year.
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our 17,000 diverse employees delivered revenue of $5.2 billion in 2021. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.
________________________
1 AvN® is a trademark of World Water Works, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005488/en/
Contact information
Media
Houston Spencer
+1.914.240.3046
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
